Friedrich Graf Finckenstein
Showing 1–1 of 1 transcripts.
- Milken Institute1h 1m
The Next Wave of Immunotherapy and Cancer Treatments | Milken Institute Global Conference 2024
Marc Hurlbert, Gina Carithers, Friedrich Graf Finckenstein, Anusha Kalbasi, Connie Pfeiffer, Sunil Verma, Frederick Finckenstein, Neil Verma, Anusha Singhal
Major research organizations like the Melanoma Research Alliance and the Prostate Cancer Foundation have funded over $1 billion in studies that pioneered immune checkpoint inhibitors and novel T-cell therapies for melanoma and prostate cancer. Recent advancements include the approval of Iovance's tumor-infiltrating lymphocyte treatment for solid tumors and the development of bispecific agents that reduce manufacturing delays, though challenges regarding high costs, autoimmune side effects, and the need for broader genetic screening persist. Clinical strategies are shifting toward neoadjuvant trials and combination therapies with antibody-drug conjugates to improve patient outcomes before standard care options are exhausted.